Finance

Viragen completes private placement for $5.2 million financing

Published in Vaccine Weekly, April 19th, 2006

Viragen, Inc. (VRA) announced the completion of a private placement unit offering to institutional and accredited investors providing gross proceeds of approximately $5.2 million. After fees and expenses, the company received approximately $4.7 million in net proceeds.

Dawson James Securities, a healthcare and biotechnology investment banking firm, acted as the placement agent.

Viragen intends to use the proceeds raised from this offering to continue funding its drug research and development plans, regulatory strategies and proceed with the international marketing of Multiferon in its approved territories, including Sweden where the drug was recently...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry